



KILPEST INDIA LIMITED

REGD. OFFICE & FACTORY :

7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 INDIA

Tel : 91-755 2586536, 2586537

E-mail : kilpest@bsnl.in

kilpestpl@yahoo.co.in

Visit us at : www.kilpest.com

CIN : L24211MP1972PLC001131

November 03, 2021

The Secretary,
Listing Department,
BSE Limited,
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("LODR Regulations")

This is to inform you that 3B BlackBio Biotech India Limited, a subsidiary of Kilpest India Limited ("Kilpest") has entered into Joint Venture Agreement with Mr. Harminder Singh, the existing sole promoter of HS Biolabs Ltd, United Kingdom, (hereinafter referred to as "HSB") to make a strategic investment in "HSB" by acquiring / subscribing 70% of the total paid-up share capital in the form of Equity Shares of "HSB".

The Company shall acquire 70% of the total paid-up share capital by November 30 2021, and accordingly HSB shall become a subsidiary of the Company as per the conditions set out in the Joint Venture agreement signed between the parties.

The details required under Regulation 30 of SEBI LODR Regulations read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, are enclosed as Annexure I. A business update on the aforesaid acquisition is enclosed as Annexure II for your perusal and information.

Further, pursuant to Regulation 30(8) of the SEBI LODR Regulations the enclosed disclosures and the business update are also made available on the Company's website.

Kindly take the same on record.

Yours faithfully,
For Kilpest India Limited

Navneet Kaur
Company Secretary




Annexure I

Disclosure under sub-para (1) [i.e., Acquisition(s) (including agreement to acquire)] of Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Details						
1.	Name and details of the target entity	HS Biolabs Ltd 43 Ridgeway Road, Timperley Altrincham, Cheshire, WA15, 7HA, UNITED KINGDOM ("HSB")						
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired	The acquisition does not fall within related party transactions. The promoter / promoter group have no interest in the Investee Company.						
3.	Industry to which the entity being acquired belongs	Biotechnology						
4.	Objects and effects of acquisition	1. This transaction will accelerate the manufacturing, R&D, marketing and sales processes in the UK which would give much higher product acceptability / reach to the company's products, especially in Europe for the "Made in UK" products. 2. With the R&D and manufacturing in the UK, the company's brand image in MDx segment would increase substantially.						
5.	Brief details of any governmental or regulatory approvals required for the Acquisition	None						
6.	Indicative time period for completion of the transaction	Acquisition of 70% stake to be completed by November 30, 2021						
7.	Nature of consideration (cash consideration or share swap and details of the same)	All Cash						
8.	Cost of acquisition or the price at which the shares are acquired	Acquisition of the shares of HSB will be done at mutually agreed pre-money enterprise valuation. The said pre-money enterprise valuation has not been disclosed herein due to reasons of confidentiality.						
9.	Percentage of shareholding / control acquired and /or number of shares acquired	Acquisition of equity stake of 70% will be done by acquiring / subscribing shares of HSB.						
10.	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, Country in which the acquired entity has presence	<p>HSB, a company registered under the Companies Act 2006 in England and Wales, is into Biotechnology segment. HS BioLabs Ltd is a European distributor of molecular diagnostic kits.</p> <p>Details of Turnover:</p> <table border="1"> <thead> <tr> <th>Year</th> <th>Approx. Revenue</th> </tr> </thead> <tbody> <tr> <td>FY 2020-2021 (Unaudited)</td> <td>£350,888.00</td> </tr> <tr> <td>FY 2019-2020 (Unaudited)</td> <td>£96,602.00</td> </tr> </tbody> </table> <p>HSB did not have revenue in FY 2018-2019 as it was incorporated on 19th June 2019 in United Kingdom.</p>	Year	Approx. Revenue	FY 2020-2021 (Unaudited)	£350,888.00	FY 2019-2020 (Unaudited)	£96,602.00
Year	Approx. Revenue							
FY 2020-2021 (Unaudited)	£350,888.00							
FY 2019-2020 (Unaudited)	£96,602.00							

BUSINESS UPDATE



3B BLACKBIO ACQUIRES MAJORITY STAKE IN HS BIOLABS LTD

Bhopal, November 3, 2021: 3B Blackbio Biotech India Limited (3B BlackBio), a molecular diagnostics provider based in India, has announced a deal with its European distributor, HS BioLabs Ltd based in Manchester, UK.

This agreement will allow 3B BlackBio to become a major shareholder of HS BioLabs Ltd and thereby forming its European subsidiary. With this transaction 3B BlackBio will acquire 70% shares in the new subsidiary for an undisclosed amount. HS BioLabs Ltd will be rebranded as **TRUPCR Europe Ltd**. The TRUPCR® range of kits offers one of the largest and the most unique range of molecular diagnostic assays in oncology and infectious disease.

This investment is in line with the company's vision to accelerate growth of the TRUPCR® range of molecular diagnostic kits within the European market. The European subsidiary will focus on becoming accredited for ISO13485:2016 and begin research & development as well as manufacturing. This will enhance customer service allowing the assays to be developed, supplied, and supported quickly throughout European region. The subsidiary intends to launch a range of NGS assays later in the year.

The initial investment will be used to setup R&D and Manufacturing base in Manchester, as well as increase recruitment in all areas of the business including Sales & Marketing, Production and R&D.



Dhirendra Dubey, CEO of 3B BlackBio said 'We are delighted to announce this deal which will allow us to grow quickly in one of the largest global markets. The deal is in line with our strategic plan as we look to significantly grow over the next 3 years.'


Harminder Singh, CEO of HS BioLabs Ltd said 'With the additional support from 3B BlackBio we are confident we will be able to meet our ambitious growth targets as well as start developing and manufacturing kits in the UK. This is a major milestone for both companies.'

3B BLACKBIO BIOTECH INDIA LTD

As a subsidiary of Kilpest India Limited, 3B BlackBio is an R&D driven company which develops, validates, and manufactures a range of qPCR (TRUPCR®) molecular diagnostic assays for the oncology and infectious disease markets. In addition, it is currently developing a range of NGS products (TRUNGS®) which will complement the TRUPCR® range of kits.

With over a decade of experience and more than 100 products developed and launched, the company ensures in delivering high quality patient care through our diagnostic solutions. In the solid tumor segment, the company offers markers for EGFR, KRAS, NRAS, Colorectal Panel. In Hemato-Onco segment, the company offers kits for BCR-ABL (M) Quantitative Kit (MR 4.7), PML-RaRa, AML, ALL, Paediatric Leukaemia Panels, apart from various panels for infectious diseases.

As an ISO13485:2016 accredited company, the molecular diagnostic kits are developed and manufactured in line with the highest possible standards.



HS BIOLABS LTD

HS BioLabs Ltd is a leading supplier of world class molecular diagnostics. It has exclusive European distribution rights to TRUPCR®. The company has a high level of expertise in molecular diagnostic platforms and kits. It has built a broad network of clients throughout Europe including the NHS and private labs.

With an experienced team and innovative products, HS BioLabs Ltd supplies high quality qPCR molecular diagnostic products throughout Europe. The company offers technical support and training on all their products and are committed to increasing the efficiency of laboratory testing and enhancing patient care. The company offers innovative products, with numerous advantages over current kits, making significant improvements in your laboratory testing

HS BioLabs Ltd has been set up by individuals with over 25 years of experience within the molecular diagnostic and healthcare sectors. This experience combined with an in-depth knowledge of methodologies and instrumentation allows the company to offer the best possible products and support to their customers.

For more information, please visit www.3bblackbio.com / www.kilpest.com

For more information on HS BioLabs Ltd Limited, please visit www.hsbiolabs.com